SLN
HOLD / NEUTRALMeanRevComposite
59.10
Technical
97.50
Fundamental
46.30
Rank
—
Price
15.43
Hurst
0.27
As of
Aug 11, 2026
Daily
Silence Therapeutics plc
HealthcareBiotechnologySilence Therapeutics is a biotechnology firm developing RNA-based therapies designed to silence disease-causing genes across blood disorders, heart disease, and uncommon conditions. The company's pipeline includes candidates targeting polycythemia vera, kidney diseases related to complement dysfunction, elevated lipoprotein(a) in cardiovascular patients, high cholesterol, abnormal blood lipids, and obesity, with several programs currently in clinical development stages.
Market cap
$1.2B
P/E (trailing)
—
P/E (forward)
-52.05
PEG ratio
—
Dividend yield
0.00%
Beta
1.45
52w range
4.19 – 19.87
Return on equity
-90.41%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 19.78 (+170.6%) · range 4.30–19.80
Cycle position
98/ 100 cycle scoreEXIT ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 0 · NOT READY · exit proximity 100
Conviction
15/ 100 · maturity 0%
Buildup.339
EMA entry setup.420
Fundamentals.2546
Volume profile
POC
19.72
Price vs POC
+0.3%
Overhead supply
10%
Runway
open sky
Value area 13.37–19.87 · 10% of 120d volume overhead · clean runway
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -7.95% | +0.48% | mature |
| 40d | -33.29% | +0.48% | mature |